IntrOductIOn
Unstable atherosclerotic plaques display numerous similarities with bone-erosive synovial lesions in the rheumatoid joint, especially the dominant role of inflammatory macrophages. [1] [2] [3] By amplifying inflammatory circuits and directly contributing to atherosclerotic plaque destabilisation, 4 macrophages may contribute to the enhanced cardiovascular risk in patients with rheumatoid arthritis (RA). Despite improved disease control, patients with RA have a twofold increased risk for myocardial infarction 5 with traditional cardiovascular risk factors explaining this only partially. 6 Even with mild disease activity, RA increases cardiovascular mortality substantially and is an independent risk factor for cardiovascular complications. 7 8 Premature cardiovascular death is the major cause of mortality in patients with RA. 9 We hypothesised that macrophages in patients with RA and CAD share functional abnormalities that promote inflammatory disease.
Macrophages in arthritic joints are hypermetabolic and produce excess amounts of succinate, which is sensed via GPR91 to amplify cytokine release. 10 Also, RA macrophages express high amounts of the glycolytic enzyme α-enolase, which is recognised by autoantibodies to induce cytokine production. 11 Macrophages of patients with coronary artery disease (CAD) excel in glucose uptake and overexpress the glycolytic enzyme pyruvate kinase M2, which functions as a protein kinase, phosphorylates signal transducer and activator of transcription 3 (STAT3) and boosts cytokine production. 12 The glycolytic intermediate pyruvate controls cell surface expression of immunoinhibitory programmed death-ligand 1 (PD-L1) in CAD macrophages, thus weakening protective immunity. 13 The kinase glycogen synthase kinase 3b (GSK3b), first named for the enzyme's contribution to glycogen storage, 14 is now recognised for affecting multiple signalling pathways. 15 In most cell types, including macrophages, GSK3b is constitutively active 16 and serine-9 phosphorylation results in its inactivation. 17 GSK3b's function is cell-type and context-dependent, 16 18 but the kinase was recently implicated in metabolic regulation. [19] [20] [21] [22] Mitochondria-associated membranes (MAM) are physical contacts between the endoplasmic reticulum (ER) and mitochondria. ER-to-mitochondria calcium transfer stimulates calcium-sensitive tricarboxylic acid (TCA) cycle enzymes to promote mitochondrial metabolism 23 and calcium can directly activate the mitochondrial ATPase. 24 Here, we report that macrophages from patients who have RA or CAD share a molecular phenotype of mitochondrial hyperactivation, which is Basic and translational research mechanistically linked to GSK3b de-activation. Inactivated GSK3b co-precipitates with mitochondria from patient-derived but not from healthy macrophages. Functional consequences include MAM formation, enhancing mitochondrial activation. MAM function and mitochondrial activation were linked to macrophage effector functions, specifically the release of the potent collagenase cathepsin K. The link between the hypermetabolic state and the tissue-damaging potential of inflammatory macrophages identifies GSK3b as a potential target to correct inappropriate immunity in RA and to prevent progression of atherosclerosis.
MetHOds

Patients and controls
The study population included 74 patients with RA, 68 patients with CAD and 50 age-matched healthy controls. Patients with RA fulfilled the 2010 diagnostic criteria and were positive for anti-cyclic citrullinated peptide (CCP) antibodies or for rheumatoid factor and were enrolled between January 2016 and December 2017. In parallel, patients with CAD who had at least one documented myocardial infarction (>90 days after the ischaemic event) were recruited. Clinical characteristics are given in online supplementary tables S1 and S2. Demographically matched healthy individuals were obtained from the Stanford Blood Center. They had no history of autoimmune disease, cancer, chronic viral infection or any other inflammatory syndrome. Written informed consent was obtained as appropriate.
cells and culture
Peripheral blood mononuclear cells (PBMCs) were isolated using Lymphoprep (STEMCELL Technologies). CD14+ cells were differentiated into macrophages in Roswell Park Memorial Institute (RPMI) 1640 medium (Life Technologies) supplemented with 20 ng/mL macrophage colony-stimulating factor (M-CSF) (eBioscience) and 10% fetal bovine serum (FBS) (Lonza) for 5 days as reported previously. 12 Macrophages were differentiated by stimulation with 100 U/mL IFN-γ (Sino Biologicals) and 100 ng/mL lipopolysaccharide (LPS) (Sigma-Aldrich). Macrophages were detached using StemPro Accutase Cell Dissociation (Life Technologies, Thermo Fisher). For inhibition of GSK3b, macrophages were treated with SB216763 (10 µM; Abcam). To inhibit mitochondrial calcium uptake, cells were treated with Ru360 (10 µM; Sigma-Aldrich).
statistical analysis
Unpaired t-test was applied when comparing groups, and paired t-test when analysing paired data. Pearson correlation coefficient was used for correlation analysis. All data analysed by Prism V.6 (GraphPad).
Detailed methods are provided in the online supplementary materials.
results
Increased mitochondrial activity and AtP production in macrophages from patients with rA and cAd Macrophages were generated from two patient cohorts: patients with autoantibody-positive RA and patients who had CAD-induced cardiac ischaemia. To test the metabolic competence, we analysed mitochondrial oxygen consumption rates (OCR) and extracellular acidification rates (ECAR) by Seahorse extracellular flux assays ( figure 1A) . Mitochondria from patient-derived macrophages consumed significantly more oxygen than those from healthy age-matched controls (basal OCR, figure 1B) . ATP-coupled OCR, probed by oligomycin inhibition of mitochondrial ATP synthase, was higher in disease macrophages, with CAD macrophages outpacing RA macrophages ( figure 1C) . Similarly, maximal respiration, tested by uncoupling the electron transfer chain with carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP), was higher in RA and CAD macrophages than in controls ( figure 1D ). (figure 1E=). Mitochondria from RA and CAD macrophages had explicitly more reserve capacity to work against imminent energy deficits ( figure 1E).(figure 1D ). In parallel, patient-derived cells intensified glycolysis, captured as higher ECAR (figure 1F). All cohorts had similar ratios of glycolysis to mitochondrial respiration (ECAR/OCR, figure 1G ). In line with higher oxygen consumption, mitochondrial membrane potentials, responsible for driving electron transport ( figure 1H,I ) and generation of reactive oxygen species (ROS) (figure 1J,K) were higher in RA and CAD macrophages. Mitochondrial hyperactivity was already obvious in freshly isolated monocytes (online supplementary figure S1A,B) . Increased mitochondrial respiration in the patients' cells resulted in higher ATP production ( figure 1L) . Together, these data demonstrated that patient-derived macrophages are in a state of heightened mitochondrial activity.
enhanced MAM formation and intensified er mitochondria calcium transfer in rA and cAd macrophages MAM are specialised organelle structures connecting mitochondria and the ER to transport lipids and calcium. 25 26 To gain information about the structural intactness of mitochondria, we performed co-localisation studies of proteins involved in tethering mitochondria to the ER. Inositol 1,4,5-trisphosphate receptors (IP3R), calcium channels in the ER outer membrane, connect to mitochondrial membranes through 75 KDa glucose-regulated protein (GRP75). Confocal microscopy revealed IP3R/GRP75 co-localisation to a higher degree in RA and CAD macrophages compared with healthy samples (figure 2A). Quantification confirmed a significantly higher protein co-localisation, and thus MAM formation, in patient-derived macrophages (figure 2B). The overall signal for IP3R and GRP75 was indistinguishable in the three study cohorts (online supplementary figure S2), suggesting that increased co-localisation of the markers was reflective of structural rearrangements.
To provide biochemical evidence for accelerated MAM formation, we analysed mitochondrial calcium uptake. Representative curves of mitochondrial calcium influx (figure 2C) illustrated greater calcium uptake in patient-derived macrophages. Quantification (relative increase peak value−baseline value) verified higher calcium uptake through the MAM contact sites in patient-derived cells compared with control cells ( figure 2D ). Spontaneously increased calcium flux was confirmed for freshly isolated monocytes (online supplementary figure S1C). To assess the impact of calcium import on mitochondrial activity, RA and CAD macrophages were treated with Ru360, a specific inhibitor of mitochondrial calcium uptake. Disrupting calcium flux caused a decline in mitochondrial membrane potential (figure 2E), diminished ROS production (figure 2F) and lowered ATP generation (figure 2G).
Thus, the signature of mitochondrial hyperactivity in RA and CAD macrophages is associated with structural adaptations, physically connecting mitochondria and the ER by MAM formation to promote calcium transfer.
GsK3b is deactivated in patient-derived macrophages
Mitochondrial hyperactivity in RA and CAD macrophages raised the question how mitochondria are instructed to upregulate F0) . (E-G) Mitochondrial membrane potential (n=7 each group), mitochondrial reactive oxygen species (n=7 each group) and intracellular ATP (n=6 each group) measured after inhibiting mitochondrial calcium influx with Ru360 (10 µM). Unpaired t-test (B-D) and paired t-test (E-H). Scale bar 10 µm. *P<0.05; **P<0.01; ***P<0.001. All bar graphs show mean±SEM. CAD, coronary artery disease; ER, endoplasmic reticulum; GRP75, 75 KDa glucose-regulated protein; HC, healthy control; IP3R, inositol 1,4,5-trisphosphate receptor; RA, rheumatoid arthritis; TMRM, tetramethylrhodamine methyl ester.
multiple of their functional domains. The kinase GSK3b has recently been recognised as a regulator of cellular metabolism. [20] [21] [22] In most cell types, including macrophages, GSK3b's kinase function is constitutively active. 16 To test for the activation status, we quantified pGSK3b-Ser9, the primary target site for inactivation. pGSK3b-Ser9 concentrations were already elevated in resting macrophages from patients with RA and CAD (figure 3B), indicating that mitochondria in these cells were primed for higher functional activity. Polarisation with LPS and IFN-γ had a minor impact on the phosphorylation status ( figure 3A,B) . Confocal imaging of ex vivo macrophages confirmed higher amounts of pGSK3b-Ser9 in patient cells ( figure 3C ). GSK3b inactivation was already present in freshly isolated monocytes ( figure 3D ).
To understand whether inactivated GSK3b was physically associated with mitochondrial membranes, we isolated mitochondrial protein fractions and probed for the presence of pGSK3b-Ser9. Deactivated GSK3b accumulated in the mitochondrial fraction of CAD macrophages and was also present in mitochondria of RA macrophages, whereas it was barely detectable in mitochondria from healthy donors ( figure 3E ). To test whether inhibition of GSK3b impacted MAM formation, we treated macrophages from healthy donors with an inhibitor (SB216763) and detected enhanced MAM-driven calcium transfer, suggestive for a role of GSK3b in regulating mitochondrial-ER communication ( figure 3F,G) .
Accumulation of β-catenin, a consequence of GSK3b inactivation, was clearly detectable in RA and CAD macrophages (figure 3H). The major upstream kinase to phosphorylate GSK3b is protein kinase B (Akt). We measured serine-473 phosphorylation of Akt and found significantly more activated Akt in patient macrophages ( figure 3I ).
These data established inactivation of GSK3b as a key event in priming mitochondria for high performance by increased MAM signalling.
GsK3b is deactivated in macrophages infiltrating into rA synovial tissue and into the atherosclerotic plaque
To investigate whether GSK3b inactivation is specific for macrophages in disease lesions, we immunostained inactive pGSK3b-Ser9 in tissue biopsies from RA synovium ( figure 4A ) and from atherosclerotic atheroma (figure 4B). CD68+ tissue macrophages accumulated in the lining layer of synovitic lesions and contained inactivated GSK3b. Similarly, CD68+ cells in the atherosclerotic plaque stained positive for pGSK3b-Ser9. In contrast, in control sections of liver, colon and lung (figure 4C-E) tissue-infiltrating macrophages stained negative for pGSK3b-Ser9. Liver cholangiocytes stained positive for pGSK3b-Ser9 and serve as positive control. Isotype control staining is shown in online supplementary figure S3. These findings indicate that macrophages positive for pGSK3b-Ser9 localise to disease lesions and support the concept that molecular signatures are shared among ex vivo-generated monocyte-derived macrophages and lesion-infiltrating cells.
GsK3b regulates mitochondrial activity
Structural and functional analysis suggested a mechanistic link between GSK3b deactivation, MAM-driven calcium transfer and mitochondrial hyperactivity (figures 2E,F and 3E,F). We hypothesised that GSK3b inhibition might recapitulate the total metabolic phenotype observed in RA and CAD macrophages.
Macrophages from healthy donors were treated with SB216763 to inhibit GSK3b, which resulted in accumulation of β-catenin (online supplementary figure S4A ), confirming functional deactivation of the kinase. Next, we analysed mitochondrial respiration before and after GSK3b inhibition. Seahorse-generated OCR tracings are shown in figure 5A . GSK3b inhibition stimulated mitochondrial respiration, recapitulating the phenotype observed in disease macrophages (figure 5B) and increased maximal respiration( figure 5D ). Also, ATP-coupled OCR and spare respiratory capacity increased (figure 5D,E) ( figure 5C, E) . Finally, treatment with the inhibitor led to gene induction of the main glucose uptake receptor in macrophages, glucose transporter (GLUT)-1 (online supplementary figure S4B ) and glycolytic flux increased (figure 5F).
In line with a phenotype of activated mitochondrial respiration, GSK3b inhibition in control macrophages increased mitochondrial membrane potential ( figure 5G,H) , led to formation of larger amounts of mitochondrial ROS (figure 5I,J) and allowed greater ATP production (figure 5K). These data identify GSK3b inactivation as a key event in reprogramming macrophage metabolism.
Mitochondrial activity and MAM function drive macrophage cathepsin K production
Macrophages are the main facilitator of tissue damage in both RA joints and atherosclerotic plaques. 1 2 We speculated that GSK3b-dependent metabolic reprogramming had functional implications for macrophage effector functions. We analysed transcriptome profiles for collagenases of the cathepsin family previously reported to be involved in vascular pathology. 27 A member of this family is cathepsin K, one of the most potent collagenases described in mammalian cells. 28 Cathepsin S transcripts did not separate the study cohorts, and cathepsin L was only upregulated in RA macrophages. In contrast, cathepsin K transcripts were strongly upregulated in patient-derived macrophages, being ninefold higher in cells from patients with CAD ( figure 6A ). To test whether gene induction of cathepsin K resulted in increased collagenase activity, we measured cathepsin K enzyme activity with a specific assay system. In line with transcriptome data, macrophages from patients with RA and CAD showed higher enzymatic activity (figure 6B).
To explore whether cathepsin K activity was related to disease activity in patients, we correlated clinical disease activity scores with in vitro enzyme activity in macrophages. Inflammatory burden in patients with RA was measured with Clinical Disease Activity Index. In patients with CAD, we used the number of stenotic coronary vessels assessed by coronary angiography. In both patient cohorts, more active disease in vivo was correlated with higher cathepsin K activity ( figure 6C,D) .
To establish a mechanistic connection between cathepsin K and GSK3b activity, we treated cells from healthy donors with SB216763. Transcript levels for the collagenase rose threefold (figure 6E) and cathepsin K activity increased twofold (figure 6B).
Cathepsin K activity is higher in acidic environments. 29 Macrophages possess specialised membrane-bound proton pumps to release H + to acidify the extracellular environment. These vacuolar-type H + -ATPases (V-ATPase) consume mitochondria-generated ATP; they are more effective in energy-rich cells. We explored whether the abundance of ATP in patient macrophages was associated with expression of V-ATPases. Patient-derived cells spontaneously expressed higher transcripts of V-ATPases subunits V0 and V1 (online supplementary figure S5 ) and GSK3b inactivation in healthy macrophages was followed by marked induction of V-ATPases transcripts ( figure 6F, G) . (I) Phosphoflow of pAkt-S473. Bar graph summarises MFIs from six samples in each group. Unpaired t-test was applied. *P<0.05, **P<0.01, ***P<0.001. All bar graphs show mean±SEM. Scale bar 20 µm. CAD, coronary artery disease; DAPI, 4',6-diamidino-2-phenylindole; FMO, fluorescence minus one control; GSK3b, glycogen synthase kinase 3b; HC, healthy control; mTFA, mitochondrial transcription factor A; MFI, mean fluorescence intensity; RA, rheumatoid arthritis.
We speculated that mitochondrial activity and MAM function support the tissue destructive phenotype of macrophages. To test this hypothesis, we blocked calcium transfer from the ER to mitochondria and measured cathepsin K activity. Abrogation of calcium influx into mitochondria significantly lowered cathepsin K activity in both RA and CAD macrophages ( figure 6H, I ).
In essence, metabolically active macrophages are able to activate the potent collagenase cathepsin K, and this functional domain depends on MAM function and correlates closely with the disease burden in vivo. Disengagement of GSK3b is a critical step in providing mitochondrial energy generation and a prerequisite for collagenase production and activity.
dIscussIOn
Accelerated atherosclerosis has been observed in several rheumatological diseases. The greatest impact of cardiovascular complications on patient survival can be observed in RA, where premature cardiovascular death is the major cause of mortality. 9 However, molecular mechanisms explaining acceleration of cardiovascular disease are not available. Additionally, it is unclear whether pathways for the progression of atherosclerosis are distinct or shared between patients with and without rheumatological disease. In this study, we demonstrate that macrophages from patients with RA and CAD share a molecular pathway regulated by GSK3b to promote tissue-destructive effector function.
The unexpected finding of this study was the critical role of MAMs in inflammatory macrophages. MAMs are involved in cell death signalling when uncontrolled flooding of the mitochondria with calcium induces apoptosis. Under more physiological conditions, calcium transfer is dosed and tightly regulated to fine-tune mitochondrial activity by activating mitochondrial ATPase 24 and stimulating TCA cycle enzymes. 23 Current data indicate that macrophages from patients with RA and CAD have undergone structural adaptations by increasing physiological MAM contact sites to fulfil their energy demands. Blocking calcium transfer at the MAMs abrogated mitochondrial activation and coordinately inhibited macrophage effector function by mitigating collagenase activity of cathepsin K. Other inflammatory cascades that were previously reported to be dependent on MAM formation include NLRP3 inflammasome activation 30 and formation of RIG-I/MAVS pathogen recognition receptor complexes. 31 Our data place MAMs in the centre of cellular functionality, spanning from host defence to regulation of innate immunity and tissue destruction. In a simplistic model, MAMs serve as connector between cellular energy production and effector function. This mechanism becomes pathogenic when providing energy for tissue-destructive behaviour, thus sustaining conditions of sterile chronic inflammation. Remodelling of the MAM, and with it enhancement of mitochondrial activity, occurs early in the life cycle of macrophages and is already present in precursor monocytes.
The main molecular defect of chronic inflammatory macrophages identified in this study is inactivation of GSK3b, a defect shared by circulating monocytes and differentiated macrophages. GSK3b is constitutively active in most cell types, also in macrophages, and is inhibited in response to stimulation. 32 It is considered to be a regulator of survival and cellular intactness, but its eventual role is strongly cell-type and context-dependent. 16 18 It was reported that active GSK3b is associated with mitochondrial quiescence in drosophila oocytes 21 and that GSK3-deficient B cells showed higher metabolic activity and increased proliferative capacity. [20] [21] [22] The current study identifies inactivation of GSK3b as master regulator of metabolic reprogramming in macrophages. Phosphorylation of downstream targets by active GSK3b usually provides an inhibitory effect; this regulatory control of GSK3b in preventing mitochondrial hyperactivity is lost in RA and CAD macrophages. GSK3b-Ser9 localises to mitochondria and stabilises calcium transfer at MAM contact sites, a mechanism necessary to increase ATP production and to drive tissue-destructive effector function. Importantly, this pathway is shared between macrophages from patients with RA and CAD, indicating a more universal validity in chronic inflammatory diseases. Hypermetabolic macrophages could be induced by SB216763 treatment of healthy cells, a small molecule inhibitor for GSK3b and GSK3a. The functional status of GSK3a was not examined, but the consistent increase in inactivated GSK3b by flow cytometry, immunostaining and immunoblotting in patient samples focused attention to GSK3b.
Inactivation of GSK3b had direct functional consequences: it released transcriptional suppression of cathepsin K, a highly Basic and translational research potent collagenase 28 that is highly expressed in atherosclerotic lesions and in abdominal aortic aneurysms. 33 34 In murine models, cathepsin K deficiency led to smaller atherosclerotic plaques with increased lesion stability. 35 In macrophages examined here, upregulation of cathepsin K was coupled to metabolic hyperactivity and induction of other membrane channels, all functioning in concert to achieve optimal enzymatic activity. In essence, the metabolic reprogramming is part of a signature that creates a highly aggressive and proinflammatory macrophage.
Interestingly, we observed a close correlation of in vitro cathepsin K activity with disease burden in vivo. Higher cathepsin K activity in macrophages predicted more severe disease in RA and CAD, respectively. This finding underlines the functional relevance of such effector cells and gives rise to the model that metabolically reprogrammed macrophages represent a mechanistic link for the acceleration of atherosclerotic disease.
In summary, this study identified a pathogenic GSK3b-dependent pathway as a shared defect in inflammatory macrophages of patients with RA and CAD. Enhanced formation of MAM structures represents a novel molecular mechanism that drives tissue-destructive effector functions in macrophages. Targeting GSK3b, by restoring its activation status, may allow suppressing effector pathways relevant to RA as well as CAD and provide a novel therapeutic approach towards the increased cardiovascular risk of patients with RA. 
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